Legal Representation
Attorney
                                            Wm. Charles Saunders 
                                        USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents | 
|---|---|---|---|---|
| Sep 30, 2019 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... | 
| Sep 30, 2019 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... | 
| Aug 8, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... | 
| Aug 8, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... | 
| Feb 26, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... | 
| Jan 1, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... | 
| Jan 1, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... | 
| Dec 12, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... | 
| Nov 28, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... | 
| Nov 7, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... | 
| Oct 19, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... | 
| Oct 18, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... | 
| Oct 18, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... | 
| May 17, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... | 
| May 17, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... | 
| May 17, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... | 
| May 14, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... | 
| Feb 10, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... | 
| Feb 3, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... | 
Detailed Classifications
                                                Class 005
                                            
                                        Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation
                                        
                                                    
                                                    First Use Anywhere: 
0                                                    
                                                
                                                
                                                    
                                                    First Use in Commerce: 
0                                                    
                                                
                                        Classification
                                            
                                            International Classes
                                        
                                        
                                                    005